A clinical study evaluating dendritic and cytokine-induced killer cells combined with concurrent radiochemotherapy for stage IIIB non-small cell lung cancer.

@article{Zhu2015ACS,
  title={A clinical study evaluating dendritic and cytokine-induced killer cells combined with concurrent radiochemotherapy for stage IIIB non-small cell lung cancer.},
  author={Xijuan Zhu and Yuan Hao Xu and J Zhou and Xiuhua Pan},
  journal={Genetics and molecular research : GMR},
  year={2015},
  volume={14 3},
  pages={
          10228-35
        }
}
To compare the efficacy of dendritic and cytokine-induced killer cells (DC-CIK) therapy combined with concurrent radiochemotherapy on stage IIIB non-small cell lung cancer. Sixty-three patients with stage IIIB non-small cell lung cancer were randomly divided into the study and control groups. The study group, comprising 30 patients, was treated with DC-CIK combined with docetaxel-cisplatin chemotherapy and synchronization conformal radiotherapy. The control group including 33 patients was only… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

Clinical efficacy and safety of CIK plus radiotherapy for lung cancer: A meta-analysis of 16 randomized controlled trials.

  • International immunopharmacology
  • 2018
VIEW 9 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 14 REFERENCES

A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study

J Casal Rubio, JL Fírvida-Pérez, M Lázaro-Quintela, FJ Barón-Duarte
  • Cancer Chemother. Pharmacol
  • 2014
VIEW 1 EXCERPT